Wildon Farwell | Senior Director, Late Stage Clinical Development

Wildon Farwell, Senior Director, Late Stage Clinical Development, Biogen

Wildon Farwell, MD, MPH, is Senior Medical Director in Clinical Development at Biogen.  In his role, Dr. Farwell is the clinical development lead for SPINRAZA (nusinersen) at Biogen and has been part of the program since 2011.  Dr. Farwell has extensive experience in rare disease clinical development.  Prior to his work in spinal muscular atrophy (SMA), Dr. Farwell was also a Medical Director in the Safety and Benefit Risk function at Biogen where he participated in the Hemophilia and ALS programs. Prior to coming to Biogen in 2010, Dr. Farwell was Assistant Professor of Medicine at Harvard Medical School and on faculty at Brigham and Women’s Hospital and the VA Boston Healthcare System. 
Dr. Farwell holds a medical degree from University of Missouri, Columbia and has a MPH in Clinical Effectiveness from Harvard School of Public Health. 


Precision 2018 Day 3 @ 09:50

Development of Nusinersen: first and only treatment for spinal muscular atrophy (SMA)

  • Biology of SMA is due to deficiency in SMN protein production due to deletion or mutation in the SMN1 gene
  • Mechanism of action of nusinersen is to increase SMN protein production by modifying splicing of pre-mRNA from the SMN2 gene
  • Pivotal studies in infants and children with symptomatic SMA demonstrated benefit of treatment necessary for regulatory approval
  • Study in presymptomatic infants demonstrated benefit of treatment once patients diagnosed by newborn screening

back to speakers

World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257